Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Lampert Mark N
Relationship:   10% Owner
City:   San Francisco
State:   CA
   
Insider Summary:
  
   
Companies Owned :   44    
Direct Shares   110,838,010    

Indirect Shares

   88,557,834      
Direct Value   $1,424,811,955    

Indirect Value

   $1,621,009,022      
Total Shares   199,395,844      
Total Value   $3,045,820,978      


Repligen Corp $525,440,279 Dynavax Technologies Corp $68,309,353 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,652,421 Alpine Immune Sciences Inc $13,107,624 Glycomimetics Inc $165,431 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,783,247 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $26,817,195 Merus Nv $10,671,450 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $482,807 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $235,963,827 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $2,910,187 Structure Therapeutics Inc. $186,210,137 Engene Holdings Inc. $31,611,162 Allakos Inc. $19,901,704 Repligen Corp $525,440,279 Dynavax Technologies Corp $68,309,353 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,652,421 Alpine Immune Sciences Inc $13,107,624 Glycomimetics Inc $165,431 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,783,247 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $26,817,195 Merus Nv $10,671,450 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $482,807 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $235,963,827 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $2,910,187 Structure Therapeutics Inc. $186,210,137 Engene Holdings Inc. $31,611,162 Allakos Inc. $19,901,704
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    50   
    13    

     Stock price went up :
    40   
    4    
     Stock price went down :
    10   
    9    
   
     Gain/Loss Ratio :
   4.0   
   4.0   
     Percentage Gain/Loss :
   103.0%
 -82.1%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Arena Pharmaceuticals Inc ARNA Director, 10% Owner 2003-10-17 0 2003-10-17 4,520,212    Premium*  
            Repligen Corp RGEN 10% Owner 2009-05-15 3,216,850 0    Premium*  
            Dynavax Technologies Corp DVAX Indirect Beneficial Ow... 2009-06-19 6,193,051 2009-06-19 18,579,153    Premium*  
            Adolor Corp ADLR 10% Owner 2009-09-22 4,123,551 2009-09-22 12,370,653    Premium*  
            Gyre Therapeutics GYRE 10% Owner 0 2012-11-08 1,052,258    Premium*  
            Arqule Inc ARQL 10% Owner 2018-05-30 771,305 2010-04-05 12,624,219    Premium*  
            Astex Pharmaceuticals Inc ASTX 10% Owner 2010-04-20 5,583,399 2010-04-20 16,750,197    Premium*  
            Capstone Therapeutics Corp CAPS See Explanation of Res... 2011-06-27 0 2017-07-14 890,487    Premium*  
            Ligand Pharmaceuticals Inc LGND See Explanation of Res... 0 2014-03-25 130,175    Premium*  
            Icagen Inc ICGN 10% Owner 2011-09-07 0 2011-09-07 625,400    Premium*  
            Palatin Technologies Inc PTN 10% Owner 0 2014-02-27 2,494,521    Premium*  
            Neurocrine Biosciences Inc NBIX 10% Owner 2011-10-10 0 2011-10-12 3,527,700    Premium*  
            Kent International Inc KNTH See Explanation of Res... 2011-12-23 0 2011-12-23 0    Premium*  
            Chemocentryx, Inc. CCXI 10% Owner 0 2012-11-06 3,750,277    Premium*  
            Rigel Pharmaceuticals Inc RIGL 10% Owner 0 2013-06-07 7,761,738    Premium*  
            Cascadian Therapeutics, Inc CASC 10% Owner 2013-06-05 0 2015-02-05 1,898,293    Premium*  
            Tobira Therapeutics Inc TBRA See Explanation of Res... 0 2014-03-21 1,121,221    Premium*  
            Cti Biopharma Corporation CTIC See Explanation of Res... 2023-06-26 0 2023-06-26 0    Premium*  
            Infinity Pharmaceuticals Inc INFI 10% Owner 2021-02-11 534,847 2016-12-01 0    Premium*  
            XOMA Corporation XOMA Director, 10% Owner 2023-01-06 1,693,924 2023-01-06 361,774    Premium*  
            Alpine Immune Sciences Inc ALPN 10% Owner 2017-06-20 201,811 2017-05-09 0    Premium*  
            Glycomimetics Inc GLYC 10% Owner 2020-11-04 630,453 0    Premium*  
            Xenon Pharmaceuticals Inc. XENE 10% Owner 2018-03-27 59,464 2017-06-06 0    Premium*  
            Concert Pharmaceuticals, Inc. CNCE 10% Owner 2019-06-10 169,589 2017-10-19 0    Premium*  
            Syndax Pharmaceuticals Inc SNDX 10% Owner 2018-06-18 85,038 2018-06-18 0    Premium*  
            Immune Design Corp. IMDZ 10% Owner 2018-12-04 370,391 2018-12-04 0    Premium*  
            Pieris Pharmaceuticals, Inc. PIRS 10% Owner 2023-05-11 20,333,557 2019-01-30 0    Premium*  
            Calithera Biosciences, Inc. CALA 10% Owner 2020-05-21 480,432 0    Premium*  
            Five Prime Therapeutics Inc FPRX 10% Owner 2021-03-04 6,262,085 0    Premium*  
            Cytokinetics Inc CYTK See Explanation of Res... 2020-12-09 463,244 2019-12-10 0    Premium*  
            Merus Nv MRUS 10% Owner 2021-10-08 232,747 0    Premium*  
            Ideaya Biosciences, Inc. IDYA See Explanation of Res... 2021-02-02 233,150 2020-06-19 0    Premium*  
            Kymera Therapeutics, Inc. KYMR See Remarks and Footno... 2023-11-03 294,632 2020-08-21 0    Premium*  
            Eledon Pharmaceuticals Ord Shs ELDN 10% Owner 2024-05-09 220,460 0    Premium*  
            Olema Pharmaceuticals, Inc. OLMA Director, 10% Owner 2023-09-12 524,151 2023-09-14 99,556    Premium*  
            Cytomx Therapeutics, Inc. CTMX 10% Owner 2020-12-18 5,468,599 0    Premium*  
            Rain Therapeutics Inc. RAIN See Remarks; Former 10... 2024-01-25 0 2021-04-23 0    Premium*  
            Repare Therapeutics Inc. RPTX 10% Owner 2023-11-16 548,938 0    Premium*  
            Verastem, Inc. VSTM 10% Owner 2022-01-25 19,630,934 0    Premium*  
            ESSA Pharma Inc EPIX 10% Owner 2022-07-11 8,561,841 0    Premium*  
            Third Harmonic Bio, Inc. THRD 10% Owner 2022-12-20 241,309 2022-12-20 0    Premium*  
            Structure Therapeutics Inc. GPCR 10% Owner 2023-05-10 5,173,941 0    Premium*  
            Engene Holdings Inc. ENGN 10% Owner 2023-10-31 2,221,445 0    Premium*  
            Allakos Inc. ALLK 10% Owner 2024-01-16 16,312,872 0    Premium*  
* Premium Members only  

Records found :    356         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 9 of 15
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
INFI Infinity Pharmaceuticals ... 10% Owner   –       –       •   2018-11-19 4 B $1.35 $2,005,076 D/D 1,465,126 1,254,412 2.45 -
INFI Infinity Pharmaceuticals ... 10% Owner   –       –       •   2018-11-21 4 B $1.35 $6,345 D/D 4,700 1,254,993 2.37 -
XOMA XOMA Corporation 10% Owner   –       –       •   2020-03-16 4 B $15.73 $159,916 D/D 10,164 1,257,840 2.45 %
XOMA XOMA Corporation 10% Owner   –       –       •   2020-03-17 4 B $15.73 $127,648 D/D 8,113 1,265,953 2.45 %
XOMA XOMA Corporation 10% Owner   –       –       •   2020-03-18 4 B $14.52 $64,475 D/D 4,439 1,270,392 2.45 %
XOMA XOMA Corporation 10% Owner   –       –       •   2017-02-10 3 IO $0.00 $0 D/D 0 1,270,922 -
XOMA XOMA Corporation 10% Owner   –       –       •   2020-03-25 4 B $17.20 $142,129 D/D 8,264 1,278,656 2.45 %
CTIC Cti Biopharma Corporation 10% Owner   –       –       •   2018-02-09 4 B $3.00 $2,097,675 I/I 699,225 1,295,582 1.5 -
KYMR Kymera Therapeutics, Inc. See Explanation of Responses   –       –      –    2022-01-24 4 B $37.76 $10,300,637 D/D 272,767 1,343,743 2.44 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-08 4 B $11.20 $1,969,663 I/I 175,800 1,354,736 1.5 -
KYMR Kymera Therapeutics, Inc. See Explanation of Responses   –       –      –    2022-01-27 4 B $38.33 $3,676,068 D/D 95,901 1,381,602 2.44 -
KYMR Kymera Therapeutics, Inc. See Explanation of Responses   –       –      –    2022-01-31 4 B $40.70 $1,400,406 D/D 34,408 1,395,925 2.44 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-09 4 B $10.86 $2,073,938 I/I 190,900 1,487,736 1.5 -
CTIC Cti Biopharma Corporation See Explanation of Responses   –       •       •   2022-08-09 4 A $0.00 $0 I/I 1,519,999 1,526,147 0 -
XOMA XOMA Corporation Director   –       •       •   2022-09-14 4 B $17.25 $456,044 D/D 26,441 1,571,338 3.92 %
XOMA XOMA Corporation Director   –       •       •   2022-09-15 4 B $17.96 $100,138 D/D 5,575 1,576,913 3.92 %
XOMA XOMA Corporation Director   –       •       •   2022-09-23 4 B $16.50 $273,850 D/D 16,600 1,597,695 3.92 %
XOMA XOMA Corporation Director   –       •       •   2022-09-26 4 B $16.83 $107,050 D/D 6,360 1,600,716 3.92 %
XOMA XOMA Corporation Director   –       •       •   2022-09-27 4 B $16.89 $28,409 D/D 1,682 1,601,394 3.92 %
XOMA XOMA Corporation Director   –       •       •   2023-01-05 4 B $18.39 $349,319 D/D 19,000 1,617,064 3.92 %
XOMA XOMA Corporation Director   –       •       •   2023-01-06 4 B $21.98 $71,419 D/D 3,249 1,618,637 3.92 %
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-10 4 B $10.91 $2,542,659 I/I 233,000 1,635,936 1.5 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-11 4 B $11.19 $15,601 I/I 1,394 1,636,862 1.5 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-18 4 B $11.91 $197,371 I/I 16,571 1,652,562 1.5 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-19 4 B $11.93 $254,020 I/I 21,300 1,671,562 1.5 -
  356  Records found
  1   2   3   4   5   6   7   8   9  10   11   12   13   14   15      
  Page 9 of 15  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us